Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case

Currently, imatinib and dasatinib are the only tyrosine-kinase inhibitors approved in the US and Europe for the treatment of blast crisis of chronic myeloid leukemia (BC-CML) at diagnosis, while ponatinib is the only inhibitor used in patients bearing T315I mutation. Here we report the case of a 61-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bucelli, Cristina, Cattaneo, Daniele, Ferla, Valeria, Zappa, Manuela, de Benedittis, Caterina, Soverini, Simona, Iurlo, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584354/
https://www.ncbi.nlm.nih.gov/pubmed/28890835
http://dx.doi.org/10.1155/2017/6167345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584354/
https://www.ncbi.nlm.nih.gov/pubmed/28890835
http://dx.doi.org/10.1155/2017/6167345

Ejemplares similares